Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-008: pembrolizumab + lenvatinib versus docetaxel in previously treated metastatic NSCLC after platinum chemotherapy and PD-1/PD-L1 therapy
MOH_2019-05-20_006049Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Pembrolizumab + lenvatinib, Docetaxel and Lenvatinib (3 arms). Started Mar 2019; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2019-05-20_006049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-05-20_006049.